Benign Prostatic Hyperplasia Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Benign Prostatic Hyperplasia stocks.

Benign Prostatic Hyperplasia Stocks Recent News

Date Stock Title
Nov 1 LLY Lilly to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium
Nov 1 LLY Market Volatility Soars Ahead Of Elections, Tech Earnings Mixed, Strikes And Hurricanes Knock Employment Down: This Week In The Markets
Nov 1 LLY Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
Nov 1 LLY Pharma Stock Roundup: MRK, PFE, ABBV, NVS, LLY's Q3 Earnings in Focus
Nov 1 PRCT These IBD 50 Leaders Melt Gains As Stock Market Wavers
Nov 1 LLY Stocks to watch next week: Berkshire Hathaway, Super Micro, Novo Nordisk, Vistry and M&S
Nov 1 LLY Hims & Hers Health Faces Pressure Ahead of Earnings Amid Eli Lilly's GLP-1 News
Nov 1 BSX Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term
Nov 1 BSX Boston Scientific Stock Gains From Market Expansion, Innovation
Nov 1 LLY Popular Weight Loss Drug Wegovy Shows Encouraging Results in Liver Fibrosis Trial
Nov 1 BSX Business Update
Nov 1 BSX PAHC Stock Likely to Gain From Its Latest Acquisition of Zoetis
Nov 1 BSX Teleflex Q3 Earnings Top, Stock Falls on Lowered 2024 Revenue Outlook
Nov 1 LLY Eli Lilly and Company Just Missed Earnings - But Analysts Have Updated Their Models
Nov 1 LLY Why Eli Lilly Is a No-Brainer Stock to Buy on the Dip
Nov 1 LLY Eli Lilly's Zepbound sales, Pfizer wants in on weight loss drugs, AbbVie's big deal: Pharma news round up
Nov 1 BSX The Zacks Analyst Blog The Progressive, Qualcomm, GE Aerospace, S&P Global and Boston Scientific
Oct 31 LLY Eli Lilly Earnings Have Wall Street Asking New Questions About GLP-1 Drugs. Is Something Going Wrong?
Oct 31 BSX Why The Fundamentals Make Me Bullish On Boston Scientific
Oct 31 LLY Eli Lilly 'Well-Positioned' for Growth Into 2025 Despite Q3 Volatility, UBS Says
Benign Prostatic Hyperplasia

Benign prostatic hyperplasia (BPH), also called prostate enlargement, is a noncancerous increase in size of the prostate. Symptoms may include frequent urination, trouble starting to urinate, weak stream, inability to urinate, or loss of bladder control. Complications can include urinary tract infections, bladder stones, and chronic kidney problems.The cause is unclear. Risk factors include a family history, obesity, type 2 diabetes, not enough exercise, and erectile dysfunction. Medications like pseudoephedrine, anticholinergics, and calcium channel blockers may worsen symptoms. The underlying mechanism involves the prostate pressing on the urethra thereby making it difficult to pass urine out of the bladder. Diagnosis is typically based on symptoms and examination after ruling out other possible causes.Treatment options including lifestyle changes, medications, a number of procedures, and surgery. In those with mild symptoms weight loss, exercise, and decreasing caffeine intake is recommended. In those with more significant symptoms medications may include alpha blockers such as terazosin or 5α-reductase inhibitors such as finasteride. Surgical removal of part of the prostate may be carried out in those who do not improve with other measures. Alternative medicine, such as saw palmetto, does not appear to help.About 105 million people are affected globally. BPH typically begins after the age of 40. Half of males age 50 and over are affected. After the age of 80 about 90% of males are affected. Although prostate specific antigen levels may be elevated in males with BPH, the condition does not increase the risk of prostate cancer.

Browse All Tags